There was no increased risk of infections with IV iron .
Gastrointestinal AEs were reduced with IV iron .
CONCLUSION Intravenous iron therapy is not associated with an increased risk of SAEs or infections .
Infusion reactions are more pronounced with IV iron
OBJECTIVE To amass all available evidence regarding the safety of intravenous ( IV ) iron preparations to provide a true balance of efficacy and safety .
Iron dextran in the treatment of iron-deficiency anaemia of pregnancy. Haematological response and incidence of side-effects.
Sixty pregnant patients with a haemoglobin ( Hb ) less than 8 g/dl and proven iron-deficiency anaemia were r and omly allocated to two treatment groups . Group A received the usual recommended dose of iron dextran ( Imferon ; Fisons ) and group B received two-thirds of the recommended dose . A further 30 patients received oral iron ( group C ) . There was no difference in Hb value between the three groups 4 weeks after treatment or 3 months after delivery . At 6 months after delivery , a higher mean Hb value was found in the patients in group A than those in groups B and C. Significantly higher serum ferritin levels were found in group A and this difference was still present 6 months postnatally . There was no significant difference in the incidence of delayed reactions between the two groups who received iron dextran
There was no increased risk of infections with IV iron .
Gastrointestinal AEs were reduced with IV iron .
CONCLUSION Intravenous iron therapy is not associated with an increased risk of SAEs or infections .
Infusion reactions are more pronounced with IV iron
OBJECTIVE To amass all available evidence regarding the safety of intravenous ( IV ) iron preparations to provide a true balance of efficacy and safety .